A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Trial Profile

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Eribulin (Primary) ; Dacarbazine
  • Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Study 309
  • Sponsors Eisai Inc
  • Most Recent Events

    • 30 Aug 2017 Results of a histology-specific subgroup analysis in patients with liposarcoma (n=143) published in the Journal of Clinical Oncology
    • 27 Feb 2017 Results (n=446) assessing efficacy and safety of eribulin, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 19 Oct 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top